Personalized prediction for a 86 year old man who takes Entresto, Coreg, Eliquis (an AI-powered real world drug study)

Summary:

This is a personalized prediction of potential side effects and undetected conditions for up to one year, if you would have adverse effects. The study is created by eHealthMe based on data from the FDA.

What are the drugs?

Entresto has active ingredients of sacubitril; valsartan. eHealthMe is studying from 126,610 Entresto users. Check the latest studies of Entresto.
Coreg has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 49,577 Coreg users. Check the latest studies of Coreg.
Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 191,768 Eliquis users. Check the latest studies of Eliquis.

What are the conditions?

Heart fibrillation (heart rhythm disorder) is found to be associated with 3,633 drugs and 3,857 conditions by eHealthMe. Check the latest studies of Heart fibrillation.
Heart disease aggravated is found to be associated with 954 drugs and 321 conditions by eHealthMe. Check the latest studies of Heart disease aggravated.
A-fib (most common type of arrhythmia) is found to be associated with 3,039 drugs and 3,788 conditions by eHealthMe. Check the latest studies of A-fib.

Potential side effects:

Anaemia

6.04% for males aged 86 (±5) who have a-fib and heart fibrillation
6.04% for males aged 86 (±5) who have a-fib and heart disease aggravated
6.04% for males aged 86 (±5) who have heart fibrillation and heart disease aggravated

Death

10.74% for males aged 86 (±5) who take entresto
10.74% for males aged 86 (±5) who take coreg
10.74% for males aged 86 (±5) who take eliquis

Fall

5.75% for males aged 86 (±5) who have a-fib and heart fibrillation
5.75% for males aged 86 (±5) who have a-fib and heart disease aggravated
5.75% for males aged 86 (±5) who have heart fibrillation and heart disease aggravated

Gastrointestinal haemorrhage

12.61% for males aged 86 (±5) who have a-fib and heart disease aggravated
12.61% for males aged 86 (±5) who have heart fibrillation and heart disease aggravated
12.61% for males aged 86 (±5) who have a-fib and heart fibrillation

Potential co-existing conditions:

High blood cholesterol

5.28% for males aged 86 (±5) who have a-fib and heart fibrillation
5.28% for males aged 86 (±5) who have a-fib and heart disease aggravated
5.28% for males aged 86 (±5) who have heart fibrillation and heart disease aggravated

Multiple myeloma

5.37% for males aged 86 (±5) who take entresto
5.37% for males aged 86 (±5) who take coreg
5.37% for males aged 86 (±5) who take eliquis

Prostate cancer

5.84% for males aged 86 (±5) who take entresto
5.84% for males aged 86 (±5) who take coreg
5.84% for males aged 86 (±5) who take eliquis

Stroke

27.67% for males aged 86 (±5) who have a-fib and heart fibrillation
27.67% for males aged 86 (±5) who have a-fib and heart disease aggravated
27.67% for males aged 86 (±5) who have heart fibrillation and heart disease aggravated

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

How the study uses the data?

The study is based on gender, age, active ingredients of any drugs used, and more. Other drugs that have the same active ingredients (e.g. generic drugs) are considered.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

Related publications that referenced our studies

Barold, S. S., & Upton, S. , "Hyperkalemia Induced by the Sequential Administration of Metoprolol and Carvedilol", Case reports in cardiology, 2018 Jan .
Kim MS, Baek IH, "Effect of dronedarone on the pharmacokinetics of carvedilol following oral administration to rats", European Journal of Pharmaceutical Sciences, 2018 Jan .

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.